Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and Cystic Fibrosis Foundation Therapeutics Inc. Arcturus Therapeutics Ltd. has a strategic collaboration with CureVac AG to jointly discover, develop, and commercialize novel messenger RNA therapeutics. The company was founded in 2013 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARCT
CUSIPN/A
Phone972-72-220-4661
Debt
Debt-to-Equity RatioN/A
Current Ratio4.61
Quick Ratio4.61
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.99 million
Price / Sales7.61
Cash FlowN/A
Price / CashN/A
Book Value$3.20 per share
Price / Book2.89
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-10,900,000.00
Net MarginsN/A
Return on Equity-27.79%
Return on Assets-24.05%
Miscellaneous
Employees19
Outstanding Shares10,690,000
Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions
What is Arcturus Therapeutics' stock symbol?
Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."
How were Arcturus Therapeutics' earnings last quarter?
Arcturus Therapeutics Ltd (NASDAQ:ARCT) released its quarterly earnings results on Friday, August, 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.02. View Arcturus Therapeutics' Earnings History.
When is Arcturus Therapeutics' next earnings date?
What price target have analysts set for ARCT?
4 brokerages have issued 12-month price objectives for Arcturus Therapeutics' shares. Their forecasts range from $1.00 to $12.00. On average, they anticipate Arcturus Therapeutics' share price to reach $5.00 in the next year. View Analyst Ratings for Arcturus Therapeutics.
Who are some of Arcturus Therapeutics' key competitors?
Some companies that are related to Arcturus Therapeutics include Bellicum Pharmaceuticals (BLCM), Evelo Biosciences (EVLO), Arbutus Biopharma (ABUS), Corvus Pharmaceuticals (CRVS), Aquinox Pharmaceuticals (AQXP), Axovant Sciences (AXON), Catalyst Pharmaceuticals (CPRX), Seres Therapeutics (MCRB), DURECT (DRRX), Minerva Neurosciences (NERV), Tyme Technologies (TYME), Corbus Pharmaceuticals (CRBP), Innate Pharma (IPHYF), MediciNova (MNOV) and ProMetic Life Sciences (PFSCF).
Who are Arcturus Therapeutics' key executives?
Arcturus Therapeutics' management team includes the folowing people:
- Mr. Joseph E. Payne M.Sc., Founder, CEO & Pres
- Dr. Padmanabh Chivukula, Founder, COO & Chief Scientific Officer
- Ms. Rebecque J. Laba, VP of Fin. & Operations (Age 57)
- Dr. Christine Esau, VP of R&D
- Mr. Kiyoshi Tachikawa, Director of Frontier Science
Has Arcturus Therapeutics been receiving favorable news coverage?
News stories about ARCT stock have trended positive this week, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Arcturus Therapeutics earned a news sentiment score of 0.33 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.64 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Arcturus Therapeutics' major shareholders?
Which institutional investors are selling Arcturus Therapeutics stock?
How do I buy shares of Arcturus Therapeutics?
Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arcturus Therapeutics' stock price today?
One share of ARCT stock can currently be purchased for approximately $9.25.
How big of a company is Arcturus Therapeutics?
Arcturus Therapeutics has a market capitalization of $96.87 million and generates $12.99 million in revenue each year. Arcturus Therapeutics employs 19 workers across the globe.
How can I contact Arcturus Therapeutics?
Arcturus Therapeutics' mailing address is Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor, Tel Aviv L3, 6701101. The biotechnology company can be reached via phone at 972-72-220-4661 or via email at [email protected]
MarketBeat Community Rating for Arcturus Therapeutics (ARCT)
MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Vote "Outperform" if you believe ARCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
